MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
12.18
0.00 (0.00%)
Sep 28, 2026, 9:32 AM EDT - Market open
MiNK Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8.81 | 13.36 | 4.58 | 3.37 | 19.64 | 38.89 |
Cash & Short-Term Investments | 8.81 | 13.36 | 4.58 | 3.37 | 19.64 | 38.89 |
Cash Growth | 423.63% | 191.90% | 35.93% | -82.85% | -49.51% | 1345.06% |
Prepaid Expenses | 0.28 | 0.28 | 0.25 | 0.05 | 0.3 | 0 |
Other Current Assets | 0.21 | 0.21 | 0.16 | 0.18 | 0.47 | 0.74 |
Total Current Assets | 9.3 | 13.85 | 4.99 | 3.6 | 20.4 | 39.63 |
Property, Plant & Equipment | 0.32 | 0.39 | 0.73 | 0.95 | 1.07 | 0.61 |
Total Assets | 9.62 | 14.24 | 5.72 | 4.55 | 21.47 | 40.24 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.92 | 3.43 | 2.73 | 3.91 | 5.82 | 3 |
Accrued Expenses | 1.2 | 1.58 | 1.87 | 5.04 | 4.24 | 1.76 |
Current Portion of Long-Term Debt | - | 5.18 | - | - | - | - |
Other Current Liabilities | 2.45 | 2.85 | 2.36 | 2.45 | 2.62 | 11.71 |
Total Current Liabilities | 7.57 | 13.03 | 6.96 | 11.4 | 12.68 | 16.47 |
Long-Term Debt | - | - | 4.92 | - | - | - |
Other Long-Term Liabilities | 16.07 | 15.44 | 13.42 | 11.21 | 9.19 | - |
Total Liabilities | 23.64 | 28.47 | 25.31 | 22.61 | 21.87 | 16.47 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 149.22 | 143.17 | 125.23 | 115.77 | 110.83 | 107.35 |
Retained Earnings | -162.55 | -156.68 | -144.18 | -133.4 | -110.94 | -82.95 |
Comprehensive Income & Other | -0.7 | -0.72 | -0.63 | -0.43 | -0.29 | -0.63 |
Shareholders' Equity | -14.03 | -14.23 | -19.59 | -18.06 | -0.4 | 23.78 |
Total Liabilities & Equity | 9.62 | 14.24 | 5.72 | 4.55 | 21.47 | 40.24 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | 5.18 | 4.92 | - | - | - |
Net Cash (Debt) | 8.81 | 8.18 | -0.35 | 3.37 | 19.64 | 38.89 |
Net Cash Growth | - | - | - | -82.85% | -49.51% | - |
Net Cash Per Share | 1.86 | 1.92 | -0.09 | 0.98 | 5.83 | 14.94 |
Filing Date Shares Outstanding | 5.1 | 4.97 | 3.97 | 3.47 | 3.39 | 3.36 |
Total Common Shares Outstanding | 5.1 | 4.71 | 3.96 | 3.46 | 3.39 | 3.35 |
Working Capital | 1.73 | 0.82 | -1.97 | -7.8 | 7.72 | 23.17 |
Book Value Per Share | -2.75 | -3.02 | -4.94 | -5.22 | -0.12 | 7.10 |
Tangible Book Value | -14.03 | -14.23 | -19.59 | -18.06 | -0.4 | 23.78 |
Tangible Book Value Per Share | -2.75 | -3.02 | -4.94 | -5.22 | -0.12 | 7.10 |
Machinery | 1 | 1 | 1.26 | 1.45 | 1.35 | 0.78 |